Angele Kelder Department of Hematology VU University Medical Center Biography Publications Institution JoVE Articles Angele Kelder has not added a biography. If you are Angele Kelder and would like to personalize this page please email our Author Liaison for assistance. Publications Leukemic Stem Cell Frequency: a Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia PloS One. 2014 | Pubmed ID: 25244440 A Phase 2 Study of Bortezomib Combined with Either Idarubicin/cytarabine or Cytarabine/etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: a Report from the Children's Oncology Group Pediatric Blood & Cancer. Oct, 2014 | Pubmed ID: 24976003 High Class II-associated Invariant Chain Peptide Expression on Residual Leukemic Cells is Associated with Increased Relapse Risk in Acute Myeloid Leukemia Leukemia Research. Jun, 2014 | Pubmed ID: 24731748 Normal Hematopoietic Stem Cells Within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level Than Co-existing Leukemic Stem Cells PloS One. 2013 | Pubmed ID: 24244383 Interleukin-2 Receptor Alpha-chain (CD25) Expression on Leukaemic Blasts is Predictive for Outcome and Level of Residual Disease in AML European Journal of Cancer (Oxford, England : 1990). Jun, 2009 | Pubmed ID: 19321337 Correlation of Minimal Residual Disease Cell Frequency with Molecular Genotype in Patients with Acute Myeloid Leukemia Haematologica. Jan, 2009 | Pubmed ID: 19042917 Identification of a Small Subpopulation of Candidate Leukemia-initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia Stem Cells (Dayton, Ohio). Dec, 2008 | Pubmed ID: 19096043 Positive Selection for CD90 As a Purging Option in Acute Myeloid Leukemia Stem Cell Transplants Cytometry. Part B, Clinical Cytometry. Jan, 2008 | Pubmed ID: 18061946 High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2005 | Pubmed ID: 16166428 नमूना और प्रक्रिया के लिए व्यापक प्रोटोकॉल मापने योग्य अवशिष्ट रोग और ल्यूकेमिया से प्रभावित के लिए अस्थि मज्जा तीव्र माइलॉयड ल्यूकेमिया में स्टेम सेल Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 암 연구학
नमूना और प्रक्रिया के लिए व्यापक प्रोटोकॉल मापने योग्य अवशिष्ट रोग और ल्यूकेमिया से प्रभावित के लिए अस्थि मज्जा तीव्र माइलॉयड ल्यूकेमिया में स्टेम सेल Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 암 연구학
